Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17Prostatic Neoplasms 6Ovarian Neoplasms 6Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Stomach Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Multiple Myeloma 2Mouth Neoplasms 2Lymphoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancers 1Skin Diseases 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Cancers × ipatasertib × Clear all
NCT01090960 2016-07-04

A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors

Genentech, Inc.

Phase 1 Completed
52 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡